首页> 美国卫生研究院文献>Oncology Letters >Inhibition of hepatocellular carcinoma growth by adenovirus-mediated expression of human telomerase reverse transcriptase COOH-27 terminal polypeptide in mice
【2h】

Inhibition of hepatocellular carcinoma growth by adenovirus-mediated expression of human telomerase reverse transcriptase COOH-27 terminal polypeptide in mice

机译:腺病毒介导的人类端粒酶逆转录酶COOH-27末端多肽在小鼠肝细胞癌中的生长抑制作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A 27-kDa C-terminal fragment of human telomerase reverse transcriptase, hTERTC27, has previously been reported to inhibit the growth and tumorigenicity of HeLa human cervical cancer cells and U87-MG human glioblastoma multiforme cells. However, the antitumor effects of hTERTC27 in hepatoma and its underlying mechanisms are unclear. In the current study, the therapeutic effect of hTERTC27, mediated by recombinant adenovirus, in hepatocellular carcinoma (HCC) was explored in vitro and in vivo to investigate the possible mechanisms. The results indicated that recombinant adenovirus carrying hTERTC27 (rAdv-hTERTC27) effectively inhibited the growth and induced apoptosis of the Hepa 1–6 HCC cells. Dendritic cells transduced with rAdv-hTERTC27 were highly effective at inducing antigen-specific T cell proliferation and increasing the activated cytotoxicity of T cells against Hepa 1–6 cells. HCC was inhibited significantly when a single dose of 5×107 pfu rAdv-hTERTC27 was administered intravenously. In summary, the results of this study demonstrated that rAdv-hTERTC27 may serve as a reagent for intravenous administration when combined with telomerase-based gene therapy and immunotherapy for cancer.
机译:先前已经报道了人类端粒酶逆转录酶hTERTC27的27 kDa C端片段抑制HeLa人宫颈癌细胞和U87-MG人胶质母细胞瘤多形细胞的生长和致瘤性。然而,hTERTC27在肝癌中的抗肿瘤作用及其潜在机制尚不清楚。在当前的研究中,在体外和体内研究了重组腺病毒介导的hTERTC27在肝细胞癌(HCC)中的治疗作用,以研究其可能的机制。结果表明,携带hTERTC27(rAdv-hTERTC27)的重组腺病毒可有效抑制Hepa 1–6 HCC细胞的生长并诱导其凋亡。用rAdv-hTERTC27转导的树突状细胞在诱导抗原特异性T细胞增殖和增加T细胞对Hepa 1–6细胞的活化细胞毒性方面非常有效。静脉注射5×10 7 pfu rAdv-hTERTC27单剂可显着抑制肝癌。总之,这项研究的结果表明,rAdv-hTERTC27与基于端粒酶的基因治疗和癌症免疫治疗相结合时,可作为静脉内给药的试剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号